Praxis Precision Medicines Rises as Investors Revisit Late-2026 FDA Catalysts

Praxis Precision Medicines (PRAX) is up 7.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed investor focus on Praxis’ upcoming regulatory catalysts and a fresh Wall Street initiation that highlighted the company’s late-stage pipeline. This could also reflect momentum buying in a biotech name with two potentially market-moving FDA decisions approaching over the next few months.

Details:

A recent analyst initiation gave PRAX an Overweight rating and a $700 price target, emphasizing the commercial potential of ulixacaltamide and relutrigine.

Praxis has an FDA decision date of January 29, 2027 for ulixacaltamide in essential tremor, keeping investor attention on a possible first product launch.

In a June 29 SEC filing, the company said the FDA extended the relutrigine review to December 27, 2026 after receiving additional sensitivity analyses, while noting no new clinical studies were requested and no safety or manufacturing concerns were cited.

The company has continued commercial preparation work for relutrigine and has described the program as a potential first approved therapy for SCN2A and SCN8A developmental and epileptic encephalopathies, which may be supporting sentiment.

Sources:

Praxis Precision Medicines, SEC, TipRanks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PRAX Insider Trading Activity

$PRAX insiders have traded $PRAX stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

Here’s a breakdown of recent trading of $PRAX stock by insiders over the last 6 months:

JILL DESIMONE has made 0 purchases and 12 sales selling 11,600 shares for an estimated $3,611,334.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$PRAX Hedge Fund Activity

We have seen 185 institutional investors add shares of $PRAX stock to their portfolio, and 116 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ORBIS ALLAN GRAY LTD removed 942,692 shares (-38.1%) from their portfolio in Q2 2026, for an estimated $315,603,854
INVESCO LTD. added 476,151 shares (+775.5%) to their portfolio in Q2 2026, for an estimated $159,410,593
RA CAPITAL MANAGEMENT, L.P. removed 373,787 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $125,140,149
NORGES BANK added 342,615 shares (+7869.0%) to their portfolio in Q2 2026, for an estimated $114,704,075
PRICE T ROWE ASSOCIATES INC /MD/ added 312,147 shares (+49.5%) to their portfolio in Q2 2026, for an estimated $104,503,694
POLAR CAPITAL HOLDINGS PLC added 279,131 shares (+inf%) to their portfolio in Q2 2026, for an estimated $93,450,267
CORMORANT ASSET MANAGEMENT, LP removed 245,500 shares (-27.7%) from their portfolio in Q2 2026, for an estimated $82,190,945

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$PRAX Congressional Stock Trading

Members of Congress have traded $PRAX stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $PRAX stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/29, 07/30 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$PRAX Analyst Ratings

Wall Street analysts have issued reports on $PRAX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/02/2026

To track analyst ratings and price targets for $PRAX, check out Quiver Quantitative's $PRAX forecast page.

$PRAX Price Targets

Multiple analysts have issued price targets for $PRAX recently. We have seen 9 analysts offer price targets for $PRAX in the last 6 months, with a median target of $575.0.

Here are some recent targets:

Ami Fadia from Needham set a target price of $575.0 on 06/29/2026
Leonid Timashev from RBC Capital set a target price of $449.0 on 06/18/2026
Kambiz Yazdi from BTIG set a target price of $810.0 on 06/02/2026
Douglas Tsao from HC Wainwright & Co. set a target price of $1201.0 on 06/02/2026
David Hoang from Deutsche Bank set a target price of $374.0 on 06/02/2026
Laura Chico from Wedbush set a target price of $162.0 on 06/02/2026
Joel Beatty from Baird set a target price of $400.0 on 06/02/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.